Australian general practitioners' attitudes and knowledge of sentinel lymph node biopsy in melanoma management.


Journal

Australian journal of general practice
ISSN: 2208-7958
Titre abrégé: Aust J Gen Pract
Pays: Australia
ID NLM: 101718099

Informations de publication

Date de publication:
06 2020
Historique:
entrez: 29 5 2020
pubmed: 30 5 2020
medline: 27 5 2021
Statut: ppublish

Résumé

In Australia, the uptake of the sentinel lymph node biopsy (SLNB) appears low despite clinical practice guideline recommendations. The aim of this study was to describe the knowledge and attitudes of general practitioners (GPs) to SLNB. GPs were recruited at an annual conference and a skin cancer skills workshop, and using GP professional communications. A mixed methods approach comprised a cross-sectional questionnaire and, for a subset of participants, semi-structured interviews. Overall, 231 GPs completed the questionnaire, of whom 23 were interviewed. One-third (32%) described themselves as quite or very familiar with the guidelines, and two-thirds (68%) thought that SLNB had an important role in the management of patients with melanoma. Of GPs who would discuss SLNB with eligible patients, <40% correctly identified that SLNB is recommended for patients with an invasive melanoma >1 mm thick. GPs were generally supportive of SLNB. Familiarity with the guidelines was low, particularly regarding which patients should be considered for SLNB.

Sections du résumé

BACKGROUND AND OBJECTIVES
In Australia, the uptake of the sentinel lymph node biopsy (SLNB) appears low despite clinical practice guideline recommendations. The aim of this study was to describe the knowledge and attitudes of general practitioners (GPs) to SLNB.
METHOD
GPs were recruited at an annual conference and a skin cancer skills workshop, and using GP professional communications. A mixed methods approach comprised a cross-sectional questionnaire and, for a subset of participants, semi-structured interviews.
RESULTS
Overall, 231 GPs completed the questionnaire, of whom 23 were interviewed. One-third (32%) described themselves as quite or very familiar with the guidelines, and two-thirds (68%) thought that SLNB had an important role in the management of patients with melanoma. Of GPs who would discuss SLNB with eligible patients, <40% correctly identified that SLNB is recommended for patients with an invasive melanoma >1 mm thick.
DISCUSSION
GPs were generally supportive of SLNB. Familiarity with the guidelines was low, particularly regarding which patients should be considered for SLNB.

Identifiants

pubmed: 32464734
doi: 10.31128/AJGP-10-19-5138
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

355-362

Auteurs

Caroline G Watts (CG)

MPH, PhD, Research Fellow, Cancer Epidemiology and Prevention Research, Sydney School of Public Health, The University of Sydney, NSW; Research Fellow, Surveillance, Evaluation and Research Program, Kirby Institute, UNSW, NSW.

Andrea L Smith (AL)

MPH, PhD, Research Fellow, Centre for Healthcare Resilience and Implementation Science (CHRIS), Australian Institute of Health Innovation (AIHI), Faculty of Medicine and Health Sciences, Macquarie University, NSW.

Sam Robinson (S)

BAppPH, Research Officer, Cancer Epidemiology and Prevention Research, Sydney School of Public Health, University of Sydney, NSW.

Chiao-Han (Sharon) Chang (CS)

MD, Research Assistant, Cancer Epidemiology and Prevention Research, Sydney School of Public Health, University of Sydney, NSW.

Chris Goumas (C)

MPH, Biostatistician, Cancer Epidemiology and Prevention Research, Sydney School of Public Health, University of Sydney, NSW.

Helen Schmid (H)

MPH, Co-ordinator, Melanoma Research Program, Westmead institute for Medical Research, NSW.

John W Kelly (JW)

MD, Adjunct Professor, Monash University Department of Medicine at Alfred Health, Consultant Dermatologist, Victorian Melanoma Service, Melbourne, Vic.

Angela M Hong (AM)

MBBS, MMed, PhD, FRANZCR, Radiation Oncologist, Melanoma Institute Australia, Chris O'Brien Lifehouse, Mater Hospital North Sydney, NSW; Clinical Professor, Medicine, Central Clinical School, University of Sydney, NSW.

Richard A Scolyer (RA)

MD, Co-Medical Director, Melanoma Institute Australia, University of Sydney, Sydney, NSW; Clinical Professor, Discipline of Pathology, Faculty of Medicine and Health, University of Sydney, Sydney, NSW; Senior Staff Specialist in Anatomical Pathology, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW.

Georgina V Long (GV)

BSc, PhD, MBBS, FRACP, Co-Medical Director, Melanoma Institute Australia, Vic; Chair of Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, University of Sydney, NSW.

Andrew J Spillane (AJ)

MD, FRACS, Professor of Surgical Oncology, Northern Clinical School, School of Medicine, Faculty of Medicine and Health, University of Sydney, NSW; Surgical Oncologist, Royal North Shore and Mater Hospitals, North Sydney, NSW.

Michael Henderson (M)

MBBS, BMedSc, MD, FRACS, Professor of Surgery, University of Melbourne, Vic; Surgeon, Melanoma and Skin Service, Breast Service and Sarcoma Service, Peter MacCallum Cancer Centre, Vic.

David E Gyorki (DE)

MBBS, MD, FRACS, Consultant surgeon, Peter MacCallum Cancer Centre, Vic.

Victoria J Mar (VJ)

PhD, Director, Victorian Melanoma Service, Alfred Hospital, Melbourne, Vic; Adjunct Associate Professor, School of Public Health and Preventive Medicine, Monash University, Melbourne, Vic.

Rachael L Morton (RL)

MScMed, PhD (Clin Epi) (Hons), Director of Health Economics, NHMRC Clinical Trials Centre, Sydney Medical School, University of Sydney, NSW; Professor of Health Economics, Sydney Medical School, University of Sydney, NSW.

Robyn PM Saw (RP)

FRACS, MS, MBBS, Associate Professor in Surgery, Central Clinical School, University of Sydney, NSW; Surgical Oncologist, Melanoma Institute Australia, NSW; General Surgeon, Royal Prince Alfred Hospital, NSW.

Alex H Varey (AH)

BSc (Med), MBBS (Hons), FRACP, PhD, Medical Oncologist, Melanoma Institute Australia, Royal North Shore and Mater Hospitals, NSW; Associate Professor, Melanoma Medical Oncology, University of Sydney, NSW.

Graham J Mann (GJ)

MBBS, PhD, FRACP, Director, John Curtin School of Medical Research, Australian National University, ACT; Principal Investigator, Melanoma Institute Australia, University of Sydney, NSW.

John F Thompson (JF)

MD, Chairman, Australian Melanoma Clinical Practice Guidelines Working Party; Professor of Melanoma and Surgical Oncology, University of Sydney, Sydney, NSW; Surgeon, Royal Prince Alfred Hospital and Melanoma Institute Australia, Sydney, NSW. john.thompson@melanoma.org.au.

Anne E Cust (AE)

MPH (Hons), PhD, Head of Cancer Epidemiology and Prevention Research Group, Sydney School of Public Health and Melanoma Institute Australia, University of Sydney, NSW; Professor of Cancer Epidemiology, Sydney Medical School, University of Sydney, NSW.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH